Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Doxorubicin + Pembrolizumab |
Indication/Tumor Type | sarcoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | sarcoma | predicted - sensitive | Doxorubicin + Pembrolizumab | Phase II | Actionable | In a Phase II trial, Keytruda (pembrolizumab) and Adriamycin (doxorubicin) combination treatment resulted in a greater overall response rate (63.6% vs 22.2%, p=0.048) in patients with metastatic or unresectable anthracycline-naive soft-tissue sarcomas with a CD274 (PD-L1) H-score >=5% compared to those with a H-score less than 5% (PMID: 34475102; NCT03056001). | 34475102 |
PubMed Id | Reference Title | Details |
---|---|---|
(34475102) | Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma. | Full reference... |